Overview

Celebrex Total Knee Arthroplasty Study

Status:
Terminated
Trial end date:
2007-07-01
Target enrollment:
0
Participant gender:
All
Summary
This study will investigate the benefits of administering celecoxib (Celebrex), a selective cyclooxygenase -2 (COX-2) inhibitor, in treating osteoarthritis (OA) subjects undergoing elective unilateral primary total knee arthroplasty (TKA) from the pre-operative phase to the management of post total knee replacement pain, and through the 6 weeks of physical therapy and rehabilitation.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Pfizer
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Treatments:
Celecoxib
Criteria
Inclusion Criteria:

- The subject is a male or female 18 years or older with osteoarthritis of the knee
scheduled to undergo elective unilateral primary total knee arthroplasty because of
OA, performed under a standardized regimen of anesthesia and procedure.

Exclusion Criteria:

- Subject has a history of inflammatory arthritis (e.g. rheumatoid arthritis, ankylosing
spondylitis) other than osteoarthritis.